| Title |
Effect of verapamil on systemic exposure and safety of umeclidinium and vilanterol: a randomized and open-label study
|
|---|---|
| Published in |
International Journal of Chronic Obstructive Pulmonary Disease, March 2013
|
| DOI | 10.2147/copd.s40859 |
| Pubmed ID | |
| Authors |
Rashmi Mehta, Dennis Kelleher, Andrew Preece, Stephen Hughes, Glenn Crater |
| Abstract |
The combination of umeclidinium (UMEC), a long-acting muscarinic receptor antagonist, and vilanterol (VI), a selective long-acting β₂ agonist, is in development for the treatment of chronic obstructive pulmonary disease (COPD). This study evaluated the pharmacokinetics, safety and tolerability, and pharmacodynamics of once-daily, inhaled UMEC and UMEC/VI when co-administered with oral verapamil, a moderate P-glycoprotein transporter and moderate cytochrome P450 3A4 (CYP3A4) inhibitor frequently used by patients with COPD and cardiovascular comorbidities. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 54 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | 2% |
| Unknown | 53 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 10 | 19% |
| Student > Master | 8 | 15% |
| Student > Ph. D. Student | 7 | 13% |
| Researcher | 6 | 11% |
| Student > Bachelor | 4 | 7% |
| Other | 11 | 20% |
| Unknown | 8 | 15% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 21 | 39% |
| Agricultural and Biological Sciences | 6 | 11% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 9% |
| Nursing and Health Professions | 2 | 4% |
| Biochemistry, Genetics and Molecular Biology | 2 | 4% |
| Other | 6 | 11% |
| Unknown | 12 | 22% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 30 April 2013.
All research outputs
#20,823,121
of 25,584,565 outputs
Outputs from International Journal of Chronic Obstructive Pulmonary Disease
#2,067
of 2,571 outputs
Outputs of similar age
#159,453
of 206,591 outputs
Outputs of similar age from International Journal of Chronic Obstructive Pulmonary Disease
#11
of 15 outputs
Altmetric has tracked 25,584,565 research outputs across all sources so far. This one is in the 10th percentile – i.e., 10% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,571 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.5. This one is in the 7th percentile – i.e., 7% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 206,591 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 11th percentile – i.e., 11% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 15 others from the same source and published within six weeks on either side of this one. This one is in the 20th percentile – i.e., 20% of its contemporaries scored the same or lower than it.